WO1996007734A2 - Recombinant adenovirus comprising a chimeric penton base protein - Google Patents
Recombinant adenovirus comprising a chimeric penton base protein Download PDFInfo
- Publication number
- WO1996007734A2 WO1996007734A2 PCT/US1995/009904 US9509904W WO9607734A2 WO 1996007734 A2 WO1996007734 A2 WO 1996007734A2 US 9509904 W US9509904 W US 9509904W WO 9607734 A2 WO9607734 A2 WO 9607734A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- acid sequence
- receptor
- penton base
- gene sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N2810/405—Vectors comprising RGD peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
- C12N2810/856—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants from integrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Definitions
- the present invention relates to a recombinant adenovirus comprising a chimeric adenoviral penton base protein and the use of a recombinant adenovirus comprising a chimeric adenoviral penton base protein in gene therapy.
- Adenoviruses belong to the family Adenoviridae, which is divided into two genera, namely Mastadenovirus and Aviadenovirus.
- Adenoviruses are nonenveloped, regular icosahedrons 65-80 nm in diameter (Home et al., J. Mol. Biol.. 1 , 84-86 (1959)).
- the capsid is composed of 252 capsomeres of which 240 are hexons and 12 are pentons (Ginsberg et al.. Virology. 28. 782-783 (1966)).
- the hexons and pentons are derived from three different viral polypeptides (Maizel et al.. Virology. 36.
- the hexon comprises three identical polypeptides of 967 amino acids each, namely polypeptide II (Roberts et al.. Science. 232. 1148-1151 (1986)).
- the penton contains a penton base, which is bound to the capsid, and a fiber, which is noncovalently bound to and projects from the penton base.
- the fiber protein comprises three identical polypeptides of 582 amino acids each, namely polypeptide IV.
- the Ad2 penton base protein is an 8 X 9 nm ring- shaped complex composed of five identical protein subunits of 571 amino acids each, namely polypeptide III (Boudin et al.. Virology. 92. 125-138 (1979)). Proteins IX, VI, and Ilia are also present in the adenovirus coat and are thought to stabilize the viral capsid (Stewart et al.. Cell. 67. 145-154 (1991); Stewart et al., EMBO J.. 12(7) . 2589-2599 (1993)).
- an adenovirus attaches to a cell, it undergoes receptor-mediated internalization into clathrin-coated endocytic vesicles of the cell (Svensson et al., J. Virol.. 5_1, 687-694 (1984); Chardonnet et al. , Virology. 40, 462-477 (1970)). Virions entering the cell undergo a stepwise disassembly in which many of the viral structural proteins are shed (Greber et al., Cell. 75.
- the viral particles cause disruption of the cell endosome by a pH-dependent mechanism (Fitzgerald et al., Cell. 32. 607-617 (1983)), which is still poorly understood.
- the viral particles are then transported to the nuclear pore complex of the cell (Dales et al., Virology. 56. 465-483 (1973)), where the viral genome enters the nucleus, thus initiating infection.
- adenovirus uses two separate cellular receptors, both of which must be present, to attach to and efficiently infect a cell (Wickham et al. , Cell. 73. 309- 319 (1993)).
- the fiber protein attaches the virus to a cell by binding to an, as yet, unidentified receptor.
- the penton base binds to ⁇ v integrins.
- Integrins are a family of heterodi eric cell surface receptors that mediate cellular adhesion to the extracellular matrix molecules fibronectin, vitronectin, laminin, and collagen, as well as other molecules (Hynes, Cell. 69. 11-25 (1992)).
- Integrins are known to play important roles in cell signaling processes, including calcium mobilization, protein phosphorylation, and cytoskeletal interactions (Hynes, supra) .
- the specificity with which an integrin binds to a particular ligand, such as those associated with an adenovirus, is a function of the paired ⁇ . and ⁇ subunits of the integrin.
- 8 ⁇ D i nds to laminin integrin ot 2 & ⁇ binds to collagen and laminin
- integrin Q. 3 i-- 1 binds to collagen, laminin, and fibronectin.
- tissue types may have different complements of integrin subunits, thereby providing a mode of spatial control over integrin-ligand signal transfer or over ligand internaliza ion.
- some integrins such as those that include subunit ⁇ v , are broadly expressed on numerous cell types, whereas other integrins have a much more narrow tissue distribution.
- the integrins that include subunit ⁇ 2 are expressed only on leukocytes, such as neutrophils and macrophages
- integrins including subunit ⁇ 4 are expressed only on lymphocytes and fibroblasts
- the integrin defined by the subunits ⁇ is expressed only on platelets and megakaryocytes.
- integrin subunit complement also extends to the infectability of cells by different serotypes of adenovirus, because the particular ⁇ and ⁇ subunits dictate whether a virus can enter a cell.
- the penton base of the adenovirus serotype Ad2 binds to integrins a ⁇ 3 and ⁇ v/ 3 5 (Wickham et al. (1993), supra) .
- both receptors utilized by an adenovirus are expressed on most human cells, nearly all cells in a human body are susceptible to adenoviral infection.
- a majority of integrins have been found to recognize short linear stretches of amino acids in binding to a specific ligand.
- the tripeptide motif arg-gly-asp (RGD) , which is found in scores of matrix ligands, including laminin, fibronectin, collagen, vitronectin, and fibrinogen, has been implicated in the binding of 3 ⁇ l f ⁇ 5 ⁇ i' ⁇ ⁇ b ⁇ 3 ' ⁇ m 0 2 ' and most, if not all, of the five v - containing integrins.
- the conformation of the RGD sequence within a matrix ligand is thought to be a primary factor in integrin specificity (Pierschbacher et al., J. Biol. Chem.. 262. 17294-17298 (1987)).
- integrins which do not utilize RGD, have been found to bind similar short linear stretches of amino acids within their specific ligands.
- integrin ⁇ binds via the amino acid sequence lys-gln- ala-gly-asp (KQAGD) [SEQ ID NO:l] in fibrinogen
- the penton base sequence is highly conserved among serotypes of adenovirus and contains five copies of the RGD tripeptide motif (Neumann et al., Gene. 69. 153-157 (1988)).
- the RGD tripeptide is believed to mediate binding to ⁇ v integrins because exogenously added RGD peptides can block penton base binding and adenoviral infection (Wickham et al. (1993) , supra) , and adenoviruses that have point mutations in the RGD sequence of the penton base are restricted in their ability to infect cells (Bai et al., J. Virol.. 67. 5198- 5205 (1993)).
- the penton base genes from Ad2, Ad5, Adl2, and Ad40 serotypes of adenovirus have been sequenced. Alignment of the sequences reveals a high degree of conservation over the entire sequence, except for the N-terminus, and, in Ad2, Ad5, and Adl2, a hypervariable region that includes the RGD sequence. Only Ad40, one of two enteric adenoviral serotypes, does not have an RGD sequence. Ad2 and Ad5 are identical in the hypervariable region and contain a large insert of amino acids flanking either side of the RGD sequence. Secondary structural analysis of the hypervariable regions of the three RGD-containing penton bases predicts that, in each case, the RGD is flanked by ⁇ -helices. Such structures are believed to
- ISA/EP form the spikes seen in cryo-electron micrographic (cryo- EM) images of Ad2 penton bases (Stewart et al. (1993), supra) .
- adenoviral vectors have been used for the cell-targeted transfer of one or more recombinant genes to diseased cells or tissue in need of treatment.
- Such vectors are characterized by the further advantage of not requiring host cell proliferation for expression of adenoviral proteins (Horwitz et al., In Virology. Raven Press, New York, vol. 2, pp. 1679-1721 (1990); and Berkner, BioTechniques. £, 616 (1988)), and, if the targeted tissue for somatic gene therapy is the lung, these vectors have the added advantage of being normally trophic for the respiratory epithelium (Straus, Is Adenoviruses. Plenan Press, New York, pp. 451-496 (1984) ) .
- adenoviruses as potential vectors for human gene therapy are as follows: (i) recombination is rare; (ii) there are no known associations of human malignancies with adenoviral infections despite common human infection with adenoviruses; (iii) the adenoviral genome (which is a linear, double-stranded DNA) can be manipulated to accommodate foreign genes that range in size; (iv) an adenoviral vector does not insert its DNA into the chromosome of a cell, so its effect is impermanent and unlikely to interfere with the cell's normal function; (v) the adenovirus can infect non-dividing or terminally differentiated cells, such as cells in the brain and lungs; and (vi) live adenovirus, having as an essential characteristic the ability to replicate, has been safely used as a human vaccine (Horwitz et al.
- adenoviral entry to specific cells and/or expanding the repertoire of cells amenable to adenovirus-mediated gene therapy would be a significant improvement over the current technology.
- Targeted adenoviral gene delivery should expand the cells amenable to gene therapy, reduce the amount of adenoviral vector that is necessary to obtain gene expression in the targeted cells, as well as reduce side effects and complications associated with increasing doses of an adenovirus, such as inflammation and the transfection of normal, healthy cells.
- the present invention seeks to overcome the problem of lack of cell and tissue specificity of recombinant adenoviral gene therapy. It is an object of the present invention to provide a receptor-specific, preferably cell receptor-specific/tissue receptor-specific, recombinant adenovirus. A further object of the present invention is to provide means for generating such a recombinant adenovirus at the level of gene expression, thereby enabling purification of recombinant adenoviral particles by conventional techniques. Another object of the present invention is to provide a method of gene therapy involving the use of such a homogeneous adenovirus, without the need for additional components or further modification.
- the present invention provides a recombinant adenovirus comprising a chimeric penton base protein that selectively binds to a given receptor, preferably a cell- specific/tissue-specific receptor, an adenoviral transfer vector comprising a recombinant penton base gene for the generation of a chimeric penton base protein, and a method of using a receptor-specific recombinant adenovirus comprising a therapeutic gene in gene therapy.
- Figure 1 is a partial restriction map of an adenoviral transfer vector (pAT) .
- Figure 2 is a partial restriction map of the vector pRcPB5 ( ⁇ RGD) .
- DETAILED DESCRIPTION OF THE INVENTION The present invention provides, among other things, a recombinant adenovirus comprising a chimeric penton base protein.
- the chimeric penton base protein comprises a nonpenton base amino acid sequence, which is specific for binding to a receptor, a receptor-specific antibody domain or epitope, in addition to or in place of a wild- type penton base amino acid sequence, preferably an amino acid sequence that is specific for binding to a receptor, most preferably an RGD amino acid sequence.
- nonpenton base amino acid sequence is meant any amino acid sequence that is not found in a wild-type penton base.
- the nonpenton base sequence is less than ten amino acids, more preferably less than five amino acids, and most preferably about three amino acids.
- RGD amino acid sequence is meant the RGD amino acid sequence and the RGD amino acid sequence along with up to or including three amino acids flanking either or both sides of the RGD amino acid sequence.
- the nonpenton base amino acid sequence renders the adenovirus specific for a given receptor, preferably a cell-specific or tissue- specific receptor, or specific for a given receptor- specific antibody domain or epitope.
- the receptor is preferably one that the wild-type adenovirus does not bind or one that the wild-type adenovirus binds but with greater specificity upon the introduction of the nonpenton base amino acid sequence into the chimeric penton base protein.
- the RGD amino acid sequence of the penton base protein has been replaced at the DNA level with an amino acid binding sequence for a given receptor, receptor-specific antibody domain or epitope.
- the RGD amino acid sequence has been rendered inactive at the DNA level by mutation of the RGD amino acid sequence, such as by insertional mutagenesis, for example, or rendered conformationally inaccessible in the penton base protein, such as by insertion of a DNA sequence into or adjacent to the adenoviral penton base gene sequence, wherein "gene sequence” refers to the complete penton base gene sequence as well as any lesser gene sequences that are capable of being expressed as functional penton base protein.
- the DNA sequence is inserted near the gene sequence encoding the RGD amino acid sequence, so as to move the gene sequence encoding the RGD amino acid sequence within the penton base gene sequence such that in the chimeric penton base protein the RGD amino acid sequence is conformationally inaccessible for binding to a receptor.
- the inserted nonpenton base gene sequence that causes the conformational inaccessibility of the RGD amino acid sequence in the penton base protein is preferably one that encodes an amino acid sequence that is specific for binding to a receptor, a receptor- specific antibody domain or epitope.
- a recombinant adenovirus can be used, for example, to study receptor binding, adenoviral attachment, and adenoviral infection in vitro or in vivo.
- the above-described recombinant adenovirus additionally comprises a gene capable of being expressed in a cell to which the virus has attached or by which the virus has been internalized and preferably is one having therapeutic utility.
- the recombinant adenovirus is fiberless or further comprises a chimeric coat protein, such as a fiber or hexon, that includes an amino acid sequence that is specific for a receptor, a receptor- specific antibody domain or epitope, preferably one that is specific for the same receptor, antibody domain or epitope as the nonpenton base sequence.
- Such recombinant adenovirus can be used, for example, to study the effects of expression of the gene in a given cell or tissue in vitro or in vivo.
- the recombinant adenovirus can be used for gene therapy.
- the recombinant adenovirus comprising a chimeric penton base protein and the recombinant adenovirus that additionally comprises a gene capable of being expressed in a particular cell can be generated by use of a viral transfer vector, preferably an adenoviral transfer (pAT) vector, in accordance with the present invention.
- the viral transfer vector preferably the pAT vector, comprises a chimeric adenoviral penton base gene sequence.
- the chimeric penton base gene sequence comprises a nonpenton base sequence in place of the RGD amino acid sequence, which has been deleted, or in addition to the RGD amino acid sequence, which has been mutated or rendered conformationally inaccessible in the expressed chimeric penton base protein as described above.
- the nonpenton base sequence renders the adenovirus specific for binding to a receptor, receptor- specific antibody domain or epitope also as described above. Given that the penton base gene has been shown to be >90% conserved among 5 of the approximately 41 serotypes of adenovirus, it is expected that any one of the serotypes of adenovirus may be used as the source of the penton base gene.
- Restriction sites that are unique with respect to the adenoviral genome are introduced into the penton base gene sequence; preferably, such restriction sites are introduced into or flanking the RGD region of the penton base gene sequence by a suitable method, such as PCR mutagenesis. These unique restriction sites may be any restriction site not already present in the penton base gene, and are preferably Eco RI and/or Spe I.
- Such sites facilitate the removal, inactivation, such as by sequence alteration, of the DNA sequence encoding the RGD amino acid sequence in a given adenoviral genome, such as a wild-type adenovirus, or the rendering of the RGD amino acid sequence conformationally inaccessible, thereby altering or eliminating the ability of the penton base molecule to bind an a v integrin receptor.
- a deleted RGD amino acid sequence can be replaced with, or a mutated or conformationally inaccessible RGD sequence can be accompanied by, a different DNA sequence, preferably a DNA sequence encoding specificity for binding to a receptor, preferably a cell-specific or tissue-specific cell-surface receptor, or to a receptor-specific antibody domain or epitope, for example.
- the pAT vector is one into which any suitable receptor-specific sequence can be rapidly inserted.
- any suitable receptor-specific sequence can be rapidly inserted.
- a unique Spe I restriction site can be used to remove the RGD amino acid sequence.
- sequences also can be inserted into the penton base gene sequence without the need for unique restriction sites through PCR.
- the pAT vector preferably has either (1) unique restriction sites that allow ligation of a vector fragment with the complementing fragments of the remaining viral genomes, as described in Example 4, or (2) adequate lengths of DNA on either side of the receptor-specific or antibody domain- or epitope-specific sequence that allow efficient homologous recombination with viral DNA, as described in Example 5.
- a preferred pAT vector is shown in Figure 1, which is a partial restriction map of such a vector. The pAT of Figure l was generated as described in Example 1.
- DNA encoding short peptide sequences or protein domains capable of binding to a given receptor, preferably a specific cell or tissue receptor, and capable of being internalized by the receptor, such as the receptor that is resident on leukocytes, is preferred for insertion into the penton base gene sequence in which the RGD amino acid sequence has been deleted, mutated, or rendered conformationally inaccessible.
- a given receptor preferably a specific cell or tissue receptor
- DNA sequences such as those that encode receptor- specific antibody domains and sequences that encode antigenic epitopes recognized by specific antibodies also may be used to replace the RGD amino acid sequence.
- the size of the DNA used to replace the RGD amino acid sequence may be constrained, for example, by impeded folding of the penton base and improper assembly of the penton base/fiber complex.
- the target receptor can be any receptor that is internalized by a cell, is optimally cell-specific or tissue-specific, and desirably is expressed only on those cells or tissue to be treated.
- Tissue-specific integrins are preferred target receptors for chimeric penton base molecules for four reasons.
- the wild-type penton base uses ⁇ ,, integrins to enter cells so that the use of a related integrin molecule is more apt to be successful than the use of an unrelated receptor.
- Changing the penton base protein such that it recognizes a receptor typically will not alter viral particle attachment to cells because cell attachment is mediated by the adenoviral fiber protein. Infection of the cells to which the chimeric penton base protein has attached, however, will be generally impeded because the virus requires the presence of an ⁇ v integrin to enter the cell. Therefore, an adenovirus with altered penton bases will bind to most cells but will enter only those cells expressing the receptor (e.g., the integrin) for the chimeric penton base.
- a receptor e.g., the integrin
- Those cells unable to express the appropriate receptor nonetheless will have adenoviral particles tethered on the cell membrane because the viral particles will be unable to enter the cell. Consequently, tethered adenoviral particles will be exposed to the immune system and disposed of accordingly.
- fiber-deficient viral particles can be constructed that use the penton base as the primary cell attachment protein. It is known that fiber protein is nonessential for virion assembly or infectivity of cells (Falgout et al., J. Virology. 6.2, 622-625 (1988)). Such mutant adenoviral particles lacking fiber protein adsorb onto cells at a ten-fold lower rate.
- mutant viruses do adsorb and at a lower rate than wild- ype particles indicates that the adsorption is mediated by the penton base/o ⁇ integrin interaction, which has a 30-fold lower affinity than the fiber/fiber- receptor interaction (Wickham et al. (1993), supra) . Accordingly, both attachment and internalization can be restricted only to those cells expressing the desired tissue-specific receptor.
- an amino acid sequence with a high affinity for a given receptor such as a cell-specific or tissue-specific receptor
- Fiberless viral particles containing a chimeric penton base compared to fiber-containing viral particles, can be targeted more effectively to tissues because the altered virus is able to bind only to the cells expressing the cell-specific or tissue-specific receptor recognized by the chimeric penton base.
- the desired ligand and receptor characteristics are as described above.
- a recombinant chimeric penton base gene sequence can be moved from a pAT vector into baculovirus or a suitable prokaryotic or eukaryotic expression vector for expression and evaluation of receptor specificity, avidity, and other biochemical characteristics. Accordingly, the present invention also provides recombinant baculoviral and prokaryotic and eukaryotic expression vectors comprising a chimeric adenoviral penton base gene sequence.
- the chimeric penton base gene sequence includes a nonpenton base sequence in addition to or in place of a wild-type penton base amino acid sequence, such as an RGD amino acid sequence, which is specific for binding to a receptor.
- the wild-type penton base amino acid sequence may be deleted, mutated, or rendered conformationally inaccessible as described above with respect to the recombinant adenovirus comprising a chimeric penton base protein.
- the present invention also provides a recombinant baculovirus comprising a chimeric penton base protein and a chimeric adenoviral penton base protein comprising a nonpenton base amino acid sequence in addition to or in place of a wild-type penton base amino acid sequence, such as an RGD amino acid sequence, which is specific for binding to a receptor.
- the nonpenton base amino acid sequence is specific for binding to a receptor or a receptor-specific antibody domain or epitope as described above.
- the recombinant chimeric penton base protein rcPB protein, such as rcPB5
- Adhesion assays are used to evaluate the specificity of the interaction of the rcPB protein with its designated receptor, using the method of Wickham et al. (1993), supra. for example. Specificity and affinity of the receptor/rcPB interaction is assessed by Scatchard analysis as shown previously by Wickham et al. (1993) , supra. for wild-type penton base protein. Receptor specificity is further assessed by using antibodies and peptides specific for the targeted receptor to block rcPB5 binding to cells, using conventional methods.
- rcPB binding to fiber protein is assessed by its ability to precipitate radiolabeled fiber molecules when coupled to protein A-coated beads via an antibody to the penton base molecule.
- fiber binding can be assessed in an ELISA-based assay in which rcPB is coated onto ELISA plates followed by incubation of immobilized rcPB with soluble fiber molecules, using conventional methods. Fiber binding to the rcPB protein is then assessed by a further incubation with antibody specific for the fiber molecule, via conventional techniques.
- Virus entry and gene expression are evaluated initially by using the pAT vector containing the insert of interest to generate recombinant virus expressing the chimeric penton base protein and a marker gene, such as /3-glucuronidase.
- a marker gene such as /3-glucuronidase.
- 0-glucuronidase expression in cells infected with adenovirus containing the 0-glucuronidase gene (Ad-Gluc) can be detected as early as two hours after adding Ad-Gluc to cells. This procedure provides a quick and efficient analysis of cell entry of the recombinant virus and gene expression, and is implemented readily by an artisan of ordinary skill using conventional techniques.
- a recombinant virus which lacks a wild-type receptor binding sequence, such as the RGD amino acid sequence, in the penton base protein, can be produced in human embryonic cell line 293 (HEK 293) , which has been shown to be able to replicate recombinant adenoviral particles lacking the RGD sequence, using previously described techniques (Bai et al. (1993), supra) .
- a recombinant virus, which lacks functional fiber proteins and in which the penton base acts as both the viral attachment and internalization protein may be produced in cell lines which express the receptor to which the rcPB5 protein is targeted.
- Ad5 rcPB5 containing an insert specific for 0. ⁇ 3 can be produced in HeLa cells that express O ⁇ 2 or 293 cells transfected with the gene for 0. ⁇ 3 .
- the chimeric penton base protein may be present in the viral particle with the fiber, without the fiber (in which case the rcPB protein functions as the virus attachment and internalization protein) , with a recombinant fiber molecule that is specific for a receptor, such as a cell-specific or tissue-specific receptor, or with a recombinant coat protein that is specific for a receptor, such as a cell-specific or tissue-specific receptor. See Examples 4-9 for a further description of these embodiments of the invention.
- Recombinant adenoviruses of the present invention can be used to treat any one of a number of diseases by delivering to targeted cells corrective DNA, i.e., DNA encoding a function that is either absent or impaired, or a discrete killing agent, e.g., DNA encoding a cytotoxin that, for example, is active only intracellularly, or DNA encoding ribozy es or antisense molecules, for example.
- a discrete killing agent e.g., DNA encoding a cytotoxin that, for example, is active only intracellularly, or DNA encoding ribozy es or antisense molecules, for example.
- therapeutic gene is intended to encompass these and other embodiments of that which is more commonly referred to as gene therapy and is known to those of skill in the art.
- Diseases that are candidates for such treatment include, for example, cancer, e.g., melanoma or glioma, cystic fibrosis, genetic disorders, and pathogenic infections, including HIV infection.
- cancer e.g., melanoma or glioma
- cystic fibrosis genetic disorders
- pathogenic infections including HIV infection.
- a recombinant adenovirus having a penton base molecule recognized by 0 ⁇ 3 receptors can be used to treat melanoma or glioma
- a recombinant adenovirus recognized by ⁇ /S ⁇ receptors and expressing the cystic fibrosis transmembrane regulator (CFTR) gene can be used to treat cystic fibrosis by delivery to the epithelial cells of the lungs.
- CFTR cystic fibrosis transmembrane regulator
- various blood-related diseases can be treated by using a recombinant adenovirus recognized by o S j receptors to target neutrophils and macrophages, a recombinant adenovirus recognized by a ⁇ 1 receptors to target lymphocytes, a recombinant adenovirus recognized by ⁇ - IIb ⁇ 3 receptors to target platelets and megakaryocytes, and a recombinant adenovirus recognized by (-- ⁇ 3 integrins to target endothelial cells undergoing angiogenesis.
- excipients are also well-known to those who are skilled in the art, and are readily available. The choice of excipient will be determined in part by the particular method used to administer the recombinant adenovirus. Accordingly, there is a wide variety of suitable formulations for use in the context of the present invention. The following methods and excipients are merely exemplary and are in no way limiting.
- Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the compound dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solids or granules; (c) suspensions in an appropriate liquid; and (d) suitable emulsions.
- Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible excipients.
- Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art.
- a flavor usually sucrose and acacia or tragacanth
- pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the active ingredient, such excipients as are known in the art.
- the recombinant adenovirus of the present invention can be made into aerosol formulations to be administered via inhalation.
- aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They may also be formulated as pharmaceuticals for non-pressured preparations such as in a nebulizer or an atomizer.
- Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
- the formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
- the recombinant adenovirus of the present invention may be made into suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulas containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate. with the gene of interest, the composition employed, the method of administration, and the particular site and organism being treated. However, the dose should be sufficient to effect a therapeutic response.
- the adenoviral transfer vector also has utility in vitro. It can be used as a research tool in the study of adenoviral attachment and infection of cells and in a method of assaying receptor-ligand interaction.
- the recombinant penton base protein comprising a nonpenton base amino acid sequence in addition to or in place of a wild-type receptor binding sequence, preferably the RGD sequence, can be used in receptor-ligand assays and as adhesion proteins in vitro or in vivo, for example.
- pAT adenoviral transfer vector
- Two pairs of PCR primers were synthesized and used to amplify a region upstream (left side) and a region downstream (right side) from the RGD sequence.
- a unique Spe I site was inserted int& the antisense primer (A5a(15147)S, SEQ ID NO:14) used to amplify the upstream region between the &D sequence and a Bst XI site (15017) .
- the Bst XI site is 35 bp upstream from the
- RECTIFIED SHEET (RULE 91) ISA/EP penton base start codon (15052) .
- a unique Spe I site was ai ⁇ o inserted into the sense primer (A5a(15204)S, SEQ ID HO:13 ⁇ to amplify the right side of the gene between the ⁇ G& amino acid sequence and an Asc I site (15671) .
- the antisense primer (A5a(15659)) used to xHsplify the right side of the gene is shown as SEQ ID NO:12.
- the sense primer (A5s(14153)E; SEQ ID NO:11) for the left side of the gene includes the naturally occurring Bst XI site (15017) and also contains a unique Eco RI site 13 bp upstream from the penton base start codon, which is not in the original sequence.
- the left and right sides of the penton base gene were amplified and then cloned into pNEB 193 Rl• [Ad5 (Bam Hl/Pme I)] to create the pAT vector.
- Example 2 This example describes the construction of the base vector pRcPB ⁇ ( ⁇ RGD) for all cloning used to make a recombinant baculovirus for the expression of a recombinant chimeric Ad5 penton base protein (rcPB5 protein) and for making rcPB5 genes for incorporation into pAT and other related vectors.
- pRcPB5 a partial restriction map of which is shown in Figure 2 was created by cloning the Eco RI/Bgl
- a new sequence encoding a receptor binding domain is inserted into the unique Spe I site within the penton base gene in pRcPB5 ( ⁇ RGD) .
- the resulting vector is then used to generate recombinant baculovirus constructs so that rcPB5 protein can be generated in large quantities and evaluated.
- the Eco RI/Bgl II fragment from the pRcPB5 derivative is then cloned into pAT to make the recombinant adenovirus (Ad5 rcPB) .
- Example 3 This example describes the cloning of integrin sequences into the Spe I site of the pRcPB5 ( ⁇ RGD) vector of Example 2.
- a sequence recognized by a specific integrin receptor is cloned into the penton base cassette as follows. Overlapping sense and antisense oligonucleotides encoding a desired integrin-specific sequence are synthesized. Fox* example, the overlapping sense (Beta 3RGDs, SEQ ID NO:17.) and antisense (Beta 3RGDa, SEQ ID #0:18) oligonucleotides that encode sequences that are specific for the integrin o.
- v j3 3 (SEQ ID NO:15) and the overlapping sense (CS-ls, SEQ ID and antisense (CS-la, SEQ ID NO:22) oligonucleotides that encode sequences that are specific for the integrin ⁇ 4 /3 j are synthesized.
- the sense and antisense sequences for each are mixed and converted to full-length double- stranded sequences by filling in the unpaired nucleotides with Klenow fragment.
- the resulting double-stranded sequence is then inserted into the Spe I site of the pRcPB5 ( ⁇ RGD) vector following digestion with the endonucleotides Xba I and Spe I.
- the resulting vectors, pRcPB5( ⁇ v jS 3 ) and pRCPB5( ⁇ ) are used to create the recombinant baculovirus vectors, AcNPV rcPB5( ⁇ v/ 5 3 ) and AcNPV rcPB5( ⁇ 4 3 j ) .
- RECTIFIED SHEET (RULE 91) recombinant baculovirus vectors, AcNPV rcPB5 ( ⁇ ., ⁇ 3 ) and AcNPV rcPB5 ( ⁇ - .
- the rcPB5 protein produced in insect cells using the aforementioned baculovirus vectors is evaluated as described above. Based on the analyses in the baculovirus expression system, the Eco RI/Bgl II fragment from each of the vectors then is cloned into a pAT vector to produce the adenoviral vectors, pAT rcPB5 ( ⁇ 8 3 ) and pAT rcPB5 ( ⁇ 4 3-_) .
- This example illustrates the creation of recombinant adenovirus particles containing a wild-type fiber protein and a chimeric penton base specific for ⁇ 4 integrins (Ad5 rcPB5 ( ⁇ 4 ) :wtFiber) .
- a chimeric penton base specific for ⁇ 4 integrin (Ad5 rcPB5 ( ⁇ 4 ) rwtFiber) can be constructed through ligation of plasmid DNA with viral DNA, which chimeric construct then can be transfected into cells using standard methods.
- the pAT vector containing the desired chimeric form of penton base is digested with Xmn I to generate a l kb piece of DNA containing the receptor-specific coding sequence.
- Ad5 DNA is digested with the restriction endonuclease Xmn I, which cuts wild-type Ad5 at positions 14561 and 15710 within the Ad5 genome.
- the two larger fragments are purified away from the smaller 1 kb piece containing the sequence encoding RGD and then ligated with the Xmn I fragment from the pAT vector.
- the ligated fragments are then transfected into the appropriate cell line to produce recombinant virus.
- the virus produced from the cells can be plaque purified and verified to contain the chimeric penton base gene using PCR.
- the penton base produced in the Ad5-infected cells can be also purified, and its receptor-specificity verified.
- This example illustrates the creation of recombinant adenovirus particles containing wild-type fiber protein and chimeric penton base specific for ⁇ 4 integrins (Ad5 rcPB5 ( ⁇ 4 ) twtFiber) .
- Adenovirus particles having a chimeric penton base specific for ⁇ 4 integrins can be constructed through transfection of plasmid DNA and viral DNA into cells and generation of recombinants through homologous recombination.
- the pAT vector containing the desired chimeric form of penton base is linearized by digestion with Bam HI.
- Ad5 DNA is digested with the restriction endonuclease Xmn I which cuts wild type Ad5 at positions 14561 and 15710 within the Ad5 genome. These two unique sites within the Ad5 genome flank the Spe I site in the pAT vector.
- the linearized pAT vector and the Xmn I-digested Ad5 DNA are then transfected into the appropriate cell line, such as 293 cells, to produce a recombinant virus by homologous recombination.
- the virus produced from such cells can be plaque purified and verified to contain the chimeric penton base gene using PCR.
- the penton base produced in Ad5-infected cells also can be purified, and its receptor-specificity verified.
- Example 6 This example illustrates the creation of recombinant adenovirus particles lacking fiber protein and chimeric penton base specific for ⁇ 4 integrins (Ad5 rcPB5 ( ⁇ 4 ) : -Fiber) .
- the Ad5 rcPB5 ( ⁇ 4 ) twtFiber viral DNA can be digested with Bam HI and the 0-59 map unit (m.u.) fragment purified.
- the fiber gene can be deleted from plasmid containing the Ad5 Bam Hi/Sal I fragment (genome map units 59-100) .
- the resultant plasmid is then digested with Bam HI and Sal I, ligated to the 0-59 m.u. piece of Ad5 rcPB5 ( ⁇ 4 ) rwtFiber DNA, and transfected into cells expressing c- 4 integrins.
- the ⁇ - 4 integrins can serve as both the attachment and internalization receptors for the Ad5 rcPB5 ( ⁇ 4 ) : -Fiber virus.
- Example 7 This example illustrates the creation of recombinant adenovirus particles lacking fiber protein and containing chimeric penton base with an epitope recognized by a monoclonal antibody (antibody-specific sequence) .
- Viral DNA is isolated from an Ad5 virus lacking fiber, as in Example 6, and digested with the endonuclease Xmn I as in Example 5.
- the pAT vector containing the chimeric penton base gene containing the sequence encoding the antibody-specific epitope is prepared as in Example 5.
- the digested viral and pAT DNA is transfected into 293 cells to produce virus by homologous recombination.
- the recombinant virus is passaged and amplified by incubating cell lysates with a bispecific antibody to av integrins (expressed and internalized in 293 cells) and the antibody-specific epitope on the chimeric penton base, thereby allowing the recombinant virus to attach and infect the 293 cells.
- the virus progeny from infected cells lack the bispecific antibody so that following their purification from infected cells they can be targeted to HIV-infected cells by combining them with a bispecific antibody recognizing the antibody-specific epitope in the chimeric penton base and the HIV gpl20.
- Example 8 This example illustrates the creation of recombinant adenovirus particles containing chimeric fiber protein specific for sialyl Lewis X antigen and chimeric penton base specific for ⁇ 4 integrins [Ad5 rcPB5 ( ⁇ 4 ) :rdFiber (sLX) ] .
- the protein P-selectin binds to sialyl Lewis X antigen present on lymphocytes.
- the binding domain from P-selectin is present on the rcFiber (sLX) protein to mediate virus binding.
- the left arm (0-59 m.u.) of the Ad5 rcPB5 ( ⁇ 4 ) :wtFiber virus can be prepared by Bam HI digestion and then purified.
- the rcFiber (sLX) gene can be cloned into the plasmid containing the 59-100 m.u. fragment of the Ad5 genome.
- the rcFiber (sLX) gene then can replace the wtFiber gene.
- Ad5 fragment containing rcFiber then can be ligated to the 0-59 m.u. Ad5 fragment containing rcPB5 ( ⁇ 4 ) .
- the ligated fragment then can be transfected into cells expressing the receptors for attachment (sialyl Lewis X) and internalization ( ⁇ . 4 integrins) for the chimeric virus Ad5 rcPB5 ( ⁇ 4 ) :rcFiber (sLX) .
- Example 9 This example illustrates the creation of recombinant adenovirus particles containing chimeric hexon protein specific for sialyl Lewis X antigen, chimeric penton base specific for ⁇ 4 integrins, and lacking fiber protein [Ad5 rcPB5 ( ⁇ 4 ) : -Fiber:rcHexon (sLX) ] .
- the protein P-selectin binds to sialyl Lewis X antigen present on lymphocytes.
- the binding domain from P-selection is present within an exposed loop on wtHexon, and the resultant rcHexon (sLX) protein can mediate virus binding.
- Genes encoding rcPB5 ( ⁇ 4 ) and rcHexon (sLX) can be cloned into the pAT vector that contains the penton base gene and the region encoding the exposed loop of hexon protein. A ligation of three fragments can be performed to generate the recombinant virus.
- Ad5 rcPB5 ( ⁇ 4 ) -Fiber virus may be digested with Eco RI and Bam HI.
- the left end of the genome up to the Eco RI site and the right end of the genome down to the Bam HI site can be purified and ligated with the Eco RI/Bam HI fragment from the pAT vector containing rcPB5 ( ⁇ . 4 ) and rcHexon (sLX) .
- the ligated fragment then can be transfected into cells expressing the receptors for attachment (sialyl Lewis X) and internalization ( ⁇ 4 integrins) for the chimeric virus Ad5 rcPB5 ( ⁇ 4 ) :rcFiber (sLX) .
- Example 10 This example describes the expression of wild-type Ad5 and mutant rcPB5 ( ⁇ RGD) penton base protein in baculovirus.
- Ad5 penton base sequence was amplified with an Eco RI site inserted at the 5' end of the gene. This gene was then cloned into the pAT vector and then subcloned into the pAcSG2 baculoviral transfer vector, using methods known in the art.
- Recombinant baculovirus encoding the Ad5 penton base gene (AcNPV wtPB5) produced levels of penton base protein in insect cells that constituted approximately 50% of the total cellular protein.
- the purified wtPB5 protein migrated consistently with respect to its known molecular weight on SDS-PAGE and can mediate cell adhesion like Ad2 penton base (Wickham et al. (1993), supra) .
- the core baculoviral transfer vector, pRcPB5 ( ⁇ RDG) for expression of rcPB5 protein in the baculoviral expression system, has been used to make recombinant baculovirus, which expresses rcPB5 protein.
- This rcPB5 protein, rcPB5 ( ⁇ RGD) contains an 8 amino acid deletion in the RGD region as shown in Figure 2, which is a partial restriction map of the vector pRcPB5 ( ⁇ RGD) .
- This protein migrates consistently with respect to its known molecular weight on SDS-PAGE and, in contrast to the wild-type protein (wtPB5) , does not mediate cell adhesion, which is consistent with its lack of the RGD cell adhesion motif.
- the rcPB5 (0 ⁇ 3 ) protein mediates epithelial cell ( ⁇ . v +, ⁇ 4 -), but not lymphocyte ( ⁇ .-, c- 4 +) , adhesion; in contrast, RcPB5 ( ⁇ 4 ) supports lymphocyte, but not epithelial cell, adhesion.
- Example 11 This example illustrates the targeting of adenovirus to lymphocytes.
- the transfer vectors pAT ( ⁇ , ⁇ ) and pAT ( ⁇ 4 ) were created by cloning the Eco RI/Bgl II fragments from their respective pRcPB5 vectors into the pAT ( ⁇ RGD) vector. These pAT vectors were then linearized by Bam HI digestion and transfected with Xmn I-digested viral DNA from an Ad5 variant, which lacks the El and E3 regions and contains a j3-galactosidase reporter gene under control of a CMV promoter, to obtain recombinant Ad5 virus, namely Ad5 rcPB ( ⁇ RGD) , Ad5 rcPB ( v j3 3 ) , and Ad5 rcPB ( ⁇ 4 ) , through homologous recombination.
- the Xmn I endonuclease cuts the wild-type Ad5 at positions 14561 and 15710 within the genome, while the Bam Hl/Pme I fragment contained in the pAT vector spans the Ad5 region of 13258 to 21562. Thus, the regions of homologous overlap between the left and right viral sequences with the Bam Hl/Pme I fragment are 1303 bp and 5851 bp, respectively.
- the presence of the chimeric inserts in the Ad5 rcPB (0 ⁇ 3 ) and Ad5 rcPB ( ⁇ 4 ) viruses are verified through PCR.
- the recombinant adenovirus Ad5 rcPB ( ⁇ 4 ) is analyzed for its targeting potential in relation to wild-type Ad5 and recombinant Ad5 rcPB ( ⁇ RGD) by measuring levels of the reporter gene expression in cells exposed to each of the viruses. Delivery of 0-galactosidase to the B- lymphocyte cell line, Ramos, is significantly higher using the Ad5 rcPB ( ⁇ 4 ) virus than the Ad5 rcPB ( ⁇ RGD) and wild-type Ad5 viruses.
- ADDRESSEE Leydig, Voit & Mayer
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (synthetic)
- xi SEQUENCE DESCRIPTION: SEQ ID NO:20: TTTTCTAGAC TGCAGGCCGC CGCAGTTGCG AATGTCGCCG CG 42
- MOLECULE TYPE DNA (genomic)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95928312A EP0778889B1 (en) | 1994-09-08 | 1995-08-07 | Recombinant adenovirus comprising a chimeric penton base protein |
JP8509488A JPH10505242A (en) | 1994-09-08 | 1995-08-07 | Recombinant adenovirus containing chimeric penton base protein |
DE69535103T DE69535103D1 (en) | 1994-09-08 | 1995-08-07 | RECOMBINANT ADENOVIRUS WHICH HAS A CHIMERIC PENTON BASE |
AU32129/95A AU684220B2 (en) | 1994-09-08 | 1995-08-07 | Recombinant adenovirus comprising a chimeric penton base protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US303,162 | 1994-09-08 | ||
US08/303,162 US5559099A (en) | 1994-09-08 | 1994-09-08 | Penton base protein and methods of using same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996007734A2 true WO1996007734A2 (en) | 1996-03-14 |
WO1996007734A3 WO1996007734A3 (en) | 1996-05-09 |
Family
ID=23170789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/009904 WO1996007734A2 (en) | 1994-09-08 | 1995-08-07 | Recombinant adenovirus comprising a chimeric penton base protein |
Country Status (8)
Country | Link |
---|---|
US (3) | US5559099A (en) |
EP (2) | EP1679376A3 (en) |
JP (1) | JPH10505242A (en) |
AT (1) | ATE332363T1 (en) |
AU (1) | AU684220B2 (en) |
CA (1) | CA2198861A1 (en) |
DE (1) | DE69535103D1 (en) |
WO (1) | WO1996007734A2 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020051A2 (en) * | 1995-11-28 | 1997-06-05 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
WO1998013499A2 (en) * | 1996-09-25 | 1998-04-02 | Novartis Ag | Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors |
WO1998022607A1 (en) * | 1996-11-22 | 1998-05-28 | Rhone-Poulenc Rorer S.A. | Method for producing recombinant virus |
WO1998054346A1 (en) * | 1997-05-28 | 1998-12-03 | Genvec, Inc. | Alternatively targeted adenovirus |
US6057155A (en) * | 1995-11-28 | 2000-05-02 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6455314B1 (en) | 1998-09-11 | 2002-09-24 | Genvec, Inc. | Alternatively targeted adenovirus |
US6576456B2 (en) | 1995-02-21 | 2003-06-10 | Cornell Research Foundation, Inc. | Chimeric adenovirus fiber protein |
US6599737B1 (en) | 1998-04-30 | 2003-07-29 | Cornell Research Foundation, Inc. | Adenoviral vectors with tandem fiber proteins |
US6951755B2 (en) | 1994-09-08 | 2005-10-04 | Genvec, Inc. | Vectors and methods for gene transfer |
US7232899B2 (en) | 1996-09-25 | 2007-06-19 | The Scripps Research Institute | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
EP2168603A1 (en) | 2003-11-14 | 2010-03-31 | GenVec, Inc. | Therapeutic regimen for treating cancer |
WO2011047316A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Nucleic acid sequences encoding expandable hiv mosaic proteins |
WO2011057248A2 (en) | 2009-11-09 | 2011-05-12 | Genvec, Inc. | Simian adenovirus and methods of use |
WO2011057254A2 (en) | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
WO2012088041A1 (en) | 2010-12-20 | 2012-06-28 | Genvec, Inc. | Adenoviral vector-based dengue fever vaccine |
US8323663B2 (en) | 2005-11-10 | 2012-12-04 | Genvec, Inc. | Adenoviral vector-based foot-and-mouth disease vaccine |
EP2567967A2 (en) | 2004-04-12 | 2013-03-13 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of using adenoviral vectors to induce an immune response |
WO2013181128A1 (en) | 2012-05-29 | 2013-12-05 | Genvec, Inc. | Modified serotype 28 adenoviral vectors |
US8765146B2 (en) | 2005-08-31 | 2014-07-01 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
EP2824185A1 (en) | 2003-02-24 | 2015-01-14 | GenVec, Inc. | Materials and methods for treating disorders of the ear |
EP2880160A4 (en) * | 2012-08-03 | 2016-04-20 | Cedars Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
WO2018064523A1 (en) | 2016-09-30 | 2018-04-05 | Genvec, Inc. | Adenovectors for delivery of therapeutic genetic material into t cells |
US9951351B2 (en) | 2014-10-09 | 2018-04-24 | Genvec, Inc. | Adenoviral vector encoding human atonal homolog-1 (HATH1) |
Families Citing this family (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
GB9412844D0 (en) * | 1994-06-27 | 1994-08-17 | Medical Res Council | Improvements in or relating to therapeutic methods |
US5965541A (en) * | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5962311A (en) * | 1994-09-08 | 1999-10-05 | Genvec, Inc. | Short-shafted adenoviral fiber and its use |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
SI1445322T2 (en) | 1995-06-15 | 2012-10-30 | Crucell Holland Bv | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
CA2224907A1 (en) * | 1995-07-25 | 1997-02-13 | Introgene B.V. | Methods and means for targeted gene delivery |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
FR2751343B1 (en) * | 1996-07-16 | 1998-12-18 | Transgene Sa | PROCESS FOR THE PRESERVATION OF INFECTIOUS RECOMBINANT VIRUSES, AQUEOUS VIRAL SUSPENSION, AND USE AS A MEDICAMENT |
ATE296117T1 (en) | 1997-03-07 | 2005-06-15 | Wistar Inst | USE OF ADENOVIRAL VECTORS EXPRESSING PDGF OR VEGF TO HEAL TISSUE DEFECTS AND TO INDUCE HYPERVASCULISM IN MAMMAL TISSUES |
US6218597B1 (en) | 1997-04-03 | 2001-04-17 | University Technology Corporation | Transgenic model and treatment for heart disease |
US7276488B2 (en) * | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
US7635687B2 (en) * | 1997-06-04 | 2009-12-22 | Oxford Biomedica (Uk) Limited | Vector system |
WO1998055607A2 (en) * | 1997-06-04 | 1998-12-10 | Oxford Biomedica (Uk) Limited | Tumor targeted vector |
BR9908018A (en) * | 1998-02-17 | 2000-10-24 | Uab Research Foundation | Modified adenoviruses containing a fiber replacement protein |
WO1999047180A1 (en) * | 1998-03-20 | 1999-09-23 | Genzyme Corporation | Chimeric adenoviral vectors for targeted gene delivery |
WO1999060110A2 (en) | 1998-05-20 | 1999-11-25 | The University Of Tennessee Research Corporation | Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy |
US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
US20040043489A1 (en) * | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
US6649396B1 (en) * | 1999-02-05 | 2003-11-18 | Uab Research Foundation | Fiber receptor-independent system for the propagation of adenoviral vectors |
WO2003104467A1 (en) * | 2002-04-25 | 2003-12-18 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US7261881B1 (en) | 1999-05-20 | 2007-08-28 | Yale University | Modulation of angiogenesis and wound healing |
CA2348158A1 (en) | 1999-08-27 | 2001-03-08 | Transgene S.A. | Modified adenoviral fibre and uses thereof |
CA2385538C (en) * | 1999-09-17 | 2007-11-06 | Tgt Laboratories, S.A. De C.V. | Recombinant adenoviral vectors and their utilization in the treatment of various types of hepatic, renal and pulmonary fibrosis and hypertrophic scars |
EP1242456B1 (en) * | 1999-11-18 | 2008-10-15 | Oxford Biomedica (UK) Limited | Scfv antibodies against disease associated molecules |
EP1157999A1 (en) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
AU2001263689B2 (en) * | 2000-05-31 | 2007-03-22 | University Of Saskatchewan | Modified bovine adenovirus having altered tropism |
WO2001092549A2 (en) * | 2000-05-31 | 2001-12-06 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
US7355019B2 (en) * | 2000-06-06 | 2008-04-08 | Sibtech, Inc. | Cysteine-containing peptide tag for site-specific conjugation of proteins |
US20020164333A1 (en) * | 2000-07-10 | 2002-11-07 | The Scripps Research Institute | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
US20040033605A1 (en) * | 2000-09-20 | 2004-02-19 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells |
DE60138403D1 (en) * | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | ADENOVIRAL VECTORS FOR THE TRANSFER OF GENES IN CELLS OF THE SKELETAL MUSCULATORY OR MYOBLAST |
US6573092B1 (en) | 2000-10-10 | 2003-06-03 | Genvec, Inc. | Method of preparing a eukaryotic viral vector |
US20030202963A1 (en) * | 2000-10-12 | 2003-10-30 | Cornell Research Foundation, Inc. | Method of treating cancer |
MXPA00011713A (en) * | 2000-11-28 | 2002-05-31 | Tgt Lab S A De C V | Re-combining viral and non-viral vectors containing the human gene of the urokinase plasminogen activator and its benefit in the treatment of diverse types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars. |
EP1390476A4 (en) * | 2001-04-17 | 2005-03-30 | Vectorlogics Inc | Mosaic adenoviral vectors |
US20060275262A1 (en) * | 2001-07-26 | 2006-12-07 | Mathis James M | Conditionally replicating viruses and methods for cancer virotherapy |
GB0119852D0 (en) * | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
US7217570B2 (en) * | 2001-08-23 | 2007-05-15 | The Wistar Institute Of Anatomy And Biology | Organotypic intestinal culture and methods of use thereof |
US7247297B2 (en) * | 2001-09-14 | 2007-07-24 | The University Of Chicago | Use of DF3/MUC1 regulated expression in gene therapy |
US20040031067A1 (en) * | 2001-10-11 | 2004-02-12 | Meenhard Herlyn | Regulation of human skin healing |
GB0126378D0 (en) * | 2001-11-02 | 2002-01-02 | Oxford Biomedica Ltd | Antigen |
WO2003062400A2 (en) * | 2002-01-24 | 2003-07-31 | The Scripps Research Institute | Fiber shaft modifications for efficient targeting |
WO2003092594A2 (en) * | 2002-04-30 | 2003-11-13 | Duke University | Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use |
US20040106194A1 (en) * | 2002-08-22 | 2004-06-03 | Bett Andrew J. | Methods for propagating adenovirus and virus produced thereby |
US9701754B1 (en) | 2002-10-23 | 2017-07-11 | City Of Hope | Covalent disulfide-linked diabodies and uses thereof |
US20040248262A1 (en) | 2003-01-22 | 2004-12-09 | Koeberl Dwight D. | Constructs for expressing lysomal polypeptides |
WO2004092397A2 (en) * | 2003-04-15 | 2004-10-28 | Novartis Ag | Tmprss2 regulatory sequences and uses thereof |
US20070212675A1 (en) * | 2003-04-15 | 2007-09-13 | Novartis Ag | Flap Endonuclease (Fen1) Regulatory Sequences And Uses Thereof |
EP1631582A2 (en) * | 2003-06-10 | 2006-03-08 | University of Saskatchewan | Chimeric adenovirus capsid proteins |
US7291498B2 (en) * | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
ES2478625T3 (en) * | 2003-06-20 | 2014-07-22 | The Trustees Of The University Of Pennsylvania | Method of generating chimeric adenoviruses and uses of such chimeric adenoviruses |
EP1649028B1 (en) * | 2003-07-25 | 2012-08-22 | Genvec, Inc. | Adenoviral vector-based vaccines |
US7519698B2 (en) * | 2003-09-26 | 2009-04-14 | Ricoh Co., Ltd. | Method and system for extracting information from networked devices in a multi-protocol remote monitoring system |
CA2555412C (en) * | 2004-02-23 | 2013-06-25 | Crucell Holland B.V. | Virus purification methods |
US7473418B2 (en) | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
US20060062764A1 (en) * | 2004-08-25 | 2006-03-23 | Seshidar-Reddy Police | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
WO2006039045A2 (en) * | 2004-09-01 | 2006-04-13 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
US20070275874A1 (en) * | 2004-09-03 | 2007-11-29 | Yale University | Use of Leptin in Wound Healing |
US20060205080A1 (en) * | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
EP1869171B2 (en) * | 2005-04-11 | 2015-10-14 | Crucell Holland B.V. | Virus purification using ultrafiltration |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
US8450055B2 (en) * | 2005-08-31 | 2013-05-28 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
US9651543B2 (en) | 2005-08-31 | 2017-05-16 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
ES2363891T3 (en) | 2006-03-20 | 2011-08-18 | The Regents Of The University Of California | ANTIBODIES AGAINST THE ANTIGEN OF TRONCAL CELLS OF THE PROSTATE (PSCA) GENETICALLY MODIFIED FOR ADDRESSING TO CANCER. |
JP6092497B2 (en) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | Methods and compositions for localized secretion of anti-CTLA-4 antibodies |
US7919079B2 (en) * | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
CA2675022A1 (en) * | 2007-01-09 | 2008-07-17 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
US9078927B2 (en) | 2007-07-06 | 2015-07-14 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
EP3714906A1 (en) * | 2007-10-03 | 2020-09-30 | Cornell University | Treatment of proliferative disorders using radiolabelled antibodies to psma |
US20090202492A1 (en) * | 2008-01-25 | 2009-08-13 | University Of South Florida | Adenovirus vaccine utilizing ikk as adjuvant |
KR101661484B1 (en) * | 2008-03-14 | 2016-09-30 | 다우 글로벌 테크놀로지스 엘엘씨 | Improved process for shaping polymeric articles |
US20100069616A1 (en) * | 2008-08-06 | 2010-03-18 | The Regents Of The University Of California | Engineered antibody-nanoparticle conjugates |
MX2011004292A (en) * | 2008-11-03 | 2011-05-31 | Crucell Holland Bv | Method for the production of adenoviral vectors. |
WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
CA2752510C (en) * | 2009-02-17 | 2024-01-23 | Neil Bander | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
DK2488636T3 (en) | 2009-10-15 | 2014-06-23 | Crucell Holland Bv | PROCEDURE FOR CLEANING ADENOVIRUS PARTICLES FROM HIGH CELL DENSITY CULTURES |
DK2488635T3 (en) | 2009-10-15 | 2014-02-24 | Crucell Holland Bv | A method for purifying adenovirus of cultures with high cell density |
EP3511023A1 (en) | 2009-12-02 | 2019-07-17 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
EP2536829B1 (en) | 2010-02-15 | 2016-04-06 | Crucell Holland B.V. | Method for the production of Ad26 adenoviral vectors |
ES2887335T3 (en) | 2010-03-17 | 2021-12-22 | Univ Cornell | Vaccine against drugs of abuse based on altered adenovirus |
WO2011119773A1 (en) | 2010-03-23 | 2011-09-29 | Roeth Jeremiah F | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
CA2808556A1 (en) | 2010-09-20 | 2012-03-29 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
US9168292B2 (en) | 2010-09-27 | 2015-10-27 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
US9512429B2 (en) | 2010-12-06 | 2016-12-06 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Pharmaceutical composition comprising Nanog shRNA, and method of using Nanog shRNA to treat cancer |
AU2012225749B2 (en) | 2011-03-04 | 2015-01-22 | Intrexon Corporation | Vectors conditionally expressing protein |
US20130122038A1 (en) | 2011-11-14 | 2013-05-16 | The United States Of America As Represented By The Secretary Of The Department | Heterologous prime-boost immunization using measles virus-based vaccines |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
DK2825640T3 (en) | 2012-03-12 | 2016-08-01 | Crucell Holland Bv | BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END |
US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
CA2867950C (en) | 2012-03-22 | 2023-02-21 | Crucell Holland B.V. | Vaccine against rsv |
KR102089121B1 (en) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Oncolytic adenovirus compositions |
EP2981612B1 (en) | 2013-04-04 | 2019-07-03 | Trustees of Dartmouth College | Compositions and methods for in vivo excision of hiv-1 proviral dna |
EA039803B1 (en) | 2013-04-25 | 2022-03-15 | Янссен Вэксинс Энд Превеншн Б.В. | Stabilized soluble prefusion rsv f polypeptides |
AU2014262653B2 (en) | 2013-05-08 | 2018-07-26 | Cedars-Sinai Medical Center | Targeting corroles for tumor toxicity and MRI |
CA2914792C (en) | 2013-06-17 | 2024-02-27 | Crucell Holland B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
ES2711115T3 (en) | 2013-09-19 | 2019-04-30 | Janssen Vaccines & Prevention Bv | Improved adenovirus formulations |
KR102434541B1 (en) | 2014-01-17 | 2022-08-19 | 세다르스-신나이 메디칼 센터 | Receptor targeting constructs and uses thereof |
AU2015240460A1 (en) | 2014-04-04 | 2016-09-15 | Cedars-Sinai Medical Center | Targeting trastuzumab-resistant HER2+breast cancer with a HER3-targeting nanoparticle |
AU2015341926B2 (en) | 2014-11-04 | 2018-09-27 | Janssen Vaccines & Prevention B.V. | Therapeutic HPV16 vaccines |
EP3247807B1 (en) | 2015-01-20 | 2020-12-16 | Adcure Biotechnologies, LLC. | Detargeted adenovirus variants and related methods |
PL3271729T3 (en) | 2015-03-18 | 2021-05-04 | Janssen Vaccines & Prevention B.V. | Assays for recombinant expression systems |
AU2016249798B2 (en) | 2015-04-14 | 2022-05-26 | Janssen Vaccines And Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
EP3319634B1 (en) | 2015-07-07 | 2019-08-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
DK3319633T3 (en) | 2015-07-07 | 2021-02-01 | Janssen Vaccines & Prevention Bv | VACCINE MOD RSV |
KR20180050321A (en) | 2015-08-07 | 2018-05-14 | 이미지냅 인코포레이티드 | An antigen binding construct for targeting a molecule |
AU2016309743B2 (en) | 2015-08-20 | 2019-02-07 | Janssen Vaccines & Prevention B.V. | Therapeutic HPV18 vaccines |
WO2017060329A1 (en) | 2015-10-06 | 2017-04-13 | Janssen Vaccines & Prevention B.V. | Methods for preventing plastic-induced degradation of biologicals |
WO2017070113A1 (en) | 2015-10-19 | 2017-04-27 | The United States of America, as represented by the Secretary, Department of Health and Human Sevices | Pharmaceutical composition comprising nanog shrna, and method of using nanog shrna to treat cancer |
EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
AU2017248018A1 (en) | 2016-04-05 | 2018-09-27 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
AU2017248021B2 (en) | 2016-04-05 | 2021-08-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
CN109922829A (en) | 2016-05-02 | 2019-06-21 | 扬森疫苗与预防公司 | Therapeutic HPV vaccine combination |
AU2017264562B2 (en) | 2016-05-12 | 2023-03-09 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
MX2018014699A (en) | 2016-05-30 | 2019-02-28 | Janssen Vaccines & Prevention Bv | Stabilized pre-fusion rsv f proteins. |
JP6683847B2 (en) | 2016-06-20 | 2020-04-22 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Strong and balanced bidirectional promoter |
EP3484506A1 (en) | 2016-07-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
JP2019536468A (en) | 2016-12-12 | 2019-12-19 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Synthetic adenovirus targeting tumors and uses thereof |
WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
AU2018217935B2 (en) | 2017-02-09 | 2020-04-30 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
AU2018267971A1 (en) | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
WO2019053109A1 (en) | 2017-09-15 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against rsv |
CA3079210A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
EP3704138A1 (en) | 2017-10-31 | 2020-09-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
SG11202003398SA (en) | 2017-10-31 | 2020-05-28 | Janssen Vaccines & Prevention Bv | Adenovirus vectors and uses thereof |
CN111295391B (en) | 2017-10-31 | 2023-12-05 | 扬森疫苗与预防公司 | Adenovirus and use thereof |
PT3743106T (en) | 2018-01-23 | 2022-08-24 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and uses thereof |
TW202043256A (en) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | Prostate neoantigens and their uses |
WO2020172509A1 (en) | 2019-02-21 | 2020-08-27 | Unleash Immuno Oncolytics, Inc. | Oncolytic adenoviral vector and methods of use |
KR20220005002A (en) | 2019-04-25 | 2022-01-12 | 얀센 백신스 앤드 프리벤션 비.브이. | Recombinant Influenza Antigen |
JP2022532723A (en) | 2019-05-15 | 2022-07-19 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Co-administration of seasonal influenza vaccine and adenovirus-based respiratory syncytial virus vaccine |
MX2021013947A (en) | 2019-05-15 | 2021-12-14 | Janssen Vaccines & Prevention Bv | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine. |
JP2022547107A (en) | 2019-09-05 | 2022-11-10 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Influenza virus vaccine and its use |
WO2021064688A1 (en) | 2019-10-03 | 2021-04-08 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
CA3161800A1 (en) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
TW202144388A (en) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | Neoantigens expressed in ovarian cancer and their uses |
TW202144389A (en) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | Neoantigens expressed in multiple myeloma and their uses |
JP2023517011A (en) | 2020-03-05 | 2023-04-21 | ネオティーエックス セラピューティクス リミテッド | Methods and compositions for treating cancer using immune cells |
JP2023521194A (en) | 2020-04-13 | 2023-05-23 | ヤンセン バイオテツク,インコーポレーテツド | PSMA and STEAP1 vaccines and their uses |
WO2022009051A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
EP4338727A1 (en) | 2022-09-14 | 2024-03-20 | Roquette Freres | Adenovirus formulations |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994017832A1 (en) * | 1993-02-09 | 1994-08-18 | The Scripps Research Institute | Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4593002A (en) * | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
US4487829A (en) * | 1982-03-23 | 1984-12-11 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies against adenoviruses |
US4792525A (en) * | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4578079A (en) * | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5204445A (en) * | 1988-10-03 | 1993-04-20 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
EP0739904A1 (en) * | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5332567A (en) * | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
EP0595798B1 (en) * | 1989-10-20 | 1999-03-03 | Medarex, Inc. | Bispecific heteroantibodies with dual effector functions |
EP0496818B1 (en) * | 1989-10-20 | 1999-06-23 | Trustees Of Dartmouth College | MONOCLONAL ANTIBODY SPECIFIC FOR IgA RECEPTOR |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
GB2246779B (en) * | 1990-08-03 | 1994-08-17 | Delta Biotechnology Ltd | Tumour-associated protease inhibitors targeted to tumour cells |
GB9101550D0 (en) * | 1991-01-24 | 1991-03-06 | Mastico Robert A | Antigen-presenting chimaeric protein |
IL103059A0 (en) * | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
GB9300686D0 (en) * | 1993-01-15 | 1993-03-03 | Imp Cancer Res Tech | Compounds for targeting |
DE4311651A1 (en) * | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus for the transport of foreign DNA into higher eukaryotic cells |
US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
IT1271461B (en) * | 1993-12-01 | 1997-05-28 | Menarini Ricerche Sud Spa | ANTI-CD3 / ANTI-EGFR MONOCLONAL ANTI-BODY ANTIBODY, PROCESS FOR PRODUCTION AND ITS USE. |
US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5928944A (en) * | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
US6312699B1 (en) * | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
JPH09509329A (en) * | 1994-05-13 | 1997-09-22 | チロン ビアジーン,インコーポレイティド | Compositions and methods targeting gene delivery vehicles |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
-
1994
- 1994-09-08 US US08/303,162 patent/US5559099A/en not_active Expired - Lifetime
-
1995
- 1995-08-07 JP JP8509488A patent/JPH10505242A/en not_active Ceased
- 1995-08-07 EP EP06003302A patent/EP1679376A3/en not_active Withdrawn
- 1995-08-07 EP EP95928312A patent/EP0778889B1/en not_active Expired - Lifetime
- 1995-08-07 CA CA002198861A patent/CA2198861A1/en not_active Abandoned
- 1995-08-07 AU AU32129/95A patent/AU684220B2/en not_active Ceased
- 1995-08-07 AT AT95928312T patent/ATE332363T1/en not_active IP Right Cessation
- 1995-08-07 WO PCT/US1995/009904 patent/WO1996007734A2/en active IP Right Grant
- 1995-08-07 DE DE69535103T patent/DE69535103D1/en not_active Expired - Lifetime
-
1996
- 1996-04-17 US US08/634,060 patent/US5712136A/en not_active Expired - Lifetime
- 1996-09-06 US US08/709,515 patent/US5731190A/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994017832A1 (en) * | 1993-02-09 | 1994-08-18 | The Scripps Research Institute | Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton |
Non-Patent Citations (6)
Title |
---|
CELL, vol. 73, no. 2, 23 April 1993 CELL PRESS,CAMBRIDGE,MA,US;, pages 309-319, T.J. WICKHAM ET AL. 'Integrins alphavbeta3 and alphavbeta5 promote Adenovirus internalization but not virus attachment' cited in the application * |
GENE THER. (1995), 2(10), 750-6 CODEN: GETHEC;ISSN: 0969-7128, December 1995 WICKHAM, T. J. ET AL 'Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs' * |
J. BIOL. CHEM. (1991), 266(6), 3961-7 CODEN: JBCHA3;ISSN: 0021-9258, 25 February 1991 ALBIGES-RIZO, CORINNE ET AL 'Human adenovirus serotype 3 fiber protein. Comparison of native and recombinant proteins' * |
TRENDS IN CELL BIOLOGY 4 (2). 1994. 52-55. ISSN: 0962-8924, February 1994 NEMEROW G R ET AL 'Adenovirus entry into host cells: A role for alpha-v integrins.' * |
VIROLOGY, vol. 185, no. 1, November 1991 ACADEMIC PRESS, INC.,NEW YORK, US, pages 365-376, A. NOVELLI AND P.A. BOULANGER 'Deletion analysis of functional domains in Baculovirus-expressed Adenovirus type 2 fiber' * |
VIROLOGY, vol. 185, no. 2, December 1991 ACADEMIC PRESS, INC.,NEW YORK, US, pages 758-767, J.S. HONG AND J.A. ENGLER 'The amino terminus of the adenovirus fiber protein encodes the nuclear localization signal ' * |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6951755B2 (en) | 1994-09-08 | 2005-10-04 | Genvec, Inc. | Vectors and methods for gene transfer |
US6576456B2 (en) | 1995-02-21 | 2003-06-10 | Cornell Research Foundation, Inc. | Chimeric adenovirus fiber protein |
WO1997020051A2 (en) * | 1995-11-28 | 1997-06-05 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
EP1518933A1 (en) * | 1995-11-28 | 2005-03-30 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US6057155A (en) * | 1995-11-28 | 2000-05-02 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6329190B1 (en) | 1995-11-28 | 2001-12-11 | Genvec, Inc. | Targetting adenovirus with use of constrained peptide motifs |
US6649407B2 (en) | 1995-11-28 | 2003-11-18 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
WO1997020051A3 (en) * | 1995-11-28 | 1997-08-28 | Genvec Inc | Vectors and methods for gene transfer to cells |
US7232899B2 (en) | 1996-09-25 | 2007-06-19 | The Scripps Research Institute | Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use |
WO1998013499A2 (en) * | 1996-09-25 | 1998-04-02 | Novartis Ag | Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors |
WO1998013499A3 (en) * | 1996-09-25 | 1998-08-27 | Ciba Geigy Ag | Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors |
EP1471146A3 (en) * | 1996-09-25 | 2005-03-30 | Novartis AG | A packaging cell line expressing for use in facilitating the development of high capacity adenoviral vectors |
EP1471146A2 (en) * | 1996-09-25 | 2004-10-27 | Novartis AG | A packaging cell line expressing for use in facilitating the development of high capacity adenoviral vectors |
US6387670B1 (en) | 1996-11-22 | 2002-05-14 | Aventis Pharma, S.A. | Method for producing recombinant virus |
FR2756297A1 (en) * | 1996-11-22 | 1998-05-29 | Centre Nat Rech Scient | PROCESS FOR PRODUCING RECOMBINANT VIRUSES |
WO1998022607A1 (en) * | 1996-11-22 | 1998-05-28 | Rhone-Poulenc Rorer S.A. | Method for producing recombinant virus |
WO1998054346A1 (en) * | 1997-05-28 | 1998-12-03 | Genvec, Inc. | Alternatively targeted adenovirus |
US6599737B1 (en) | 1998-04-30 | 2003-07-29 | Cornell Research Foundation, Inc. | Adenoviral vectors with tandem fiber proteins |
US6455314B1 (en) | 1998-09-11 | 2002-09-24 | Genvec, Inc. | Alternatively targeted adenovirus |
EP2824185A1 (en) | 2003-02-24 | 2015-01-14 | GenVec, Inc. | Materials and methods for treating disorders of the ear |
EP2168603A1 (en) | 2003-11-14 | 2010-03-31 | GenVec, Inc. | Therapeutic regimen for treating cancer |
EP2567967A2 (en) | 2004-04-12 | 2013-03-13 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of using adenoviral vectors to induce an immune response |
US8765146B2 (en) | 2005-08-31 | 2014-07-01 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
US8323663B2 (en) | 2005-11-10 | 2012-12-04 | Genvec, Inc. | Adenoviral vector-based foot-and-mouth disease vaccine |
WO2011047316A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Nucleic acid sequences encoding expandable hiv mosaic proteins |
EP2853266A1 (en) | 2009-11-09 | 2015-04-01 | Genvec, Inc. | Methods of propagating monkey adenoviral vectors |
WO2011057254A2 (en) | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
WO2011057248A2 (en) | 2009-11-09 | 2011-05-12 | Genvec, Inc. | Simian adenovirus and methods of use |
WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
WO2012088041A1 (en) | 2010-12-20 | 2012-06-28 | Genvec, Inc. | Adenoviral vector-based dengue fever vaccine |
WO2013181128A1 (en) | 2012-05-29 | 2013-12-05 | Genvec, Inc. | Modified serotype 28 adenoviral vectors |
EP2880160A4 (en) * | 2012-08-03 | 2016-04-20 | Cedars Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
US10036009B2 (en) | 2012-08-03 | 2018-07-31 | Cedars-Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
US10752893B2 (en) | 2012-08-03 | 2020-08-25 | Cedars-Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
US9951351B2 (en) | 2014-10-09 | 2018-04-24 | Genvec, Inc. | Adenoviral vector encoding human atonal homolog-1 (HATH1) |
US11279951B2 (en) | 2014-10-09 | 2022-03-22 | Genvec, Inc. | Adenoviral vector encoding human atonal homolog-1 (HATH1) |
WO2018064523A1 (en) | 2016-09-30 | 2018-04-05 | Genvec, Inc. | Adenovectors for delivery of therapeutic genetic material into t cells |
Also Published As
Publication number | Publication date |
---|---|
CA2198861A1 (en) | 1996-03-14 |
US5712136A (en) | 1998-01-27 |
AU3212995A (en) | 1996-03-27 |
JPH10505242A (en) | 1998-05-26 |
EP0778889B1 (en) | 2006-07-05 |
EP1679376A3 (en) | 2006-08-16 |
EP0778889A2 (en) | 1997-06-18 |
EP1679376A2 (en) | 2006-07-12 |
WO1996007734A3 (en) | 1996-05-09 |
AU684220B2 (en) | 1997-12-04 |
US5559099A (en) | 1996-09-24 |
ATE332363T1 (en) | 2006-07-15 |
US5731190A (en) | 1998-03-24 |
DE69535103D1 (en) | 2006-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU684220B2 (en) | Recombinant adenovirus comprising a chimeric penton base protein | |
AU698254B2 (en) | Chimeric adenoviral fiber protein and methods of using same | |
AU724189B2 (en) | Vectors and methods for gene transfer to cells | |
US6455314B1 (en) | Alternatively targeted adenovirus | |
US5965541A (en) | Vectors and methods for gene transfer to cells | |
US5962311A (en) | Short-shafted adenoviral fiber and its use | |
US6951755B2 (en) | Vectors and methods for gene transfer | |
AU732770B2 (en) | Targeting adenovirus with use of constrained peptide motifs | |
KR20010034487A (en) | Adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob | |
MXPA98004203A (en) | Vectors and methods for gene transfer acelu |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2198861 Country of ref document: CA Ref country code: CA Ref document number: 2198861 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995928312 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995928312 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995928312 Country of ref document: EP |